Efficacy of nepafenac 0.3% plus dexamethasone 0.1% vs dexamethasone alone in prevention of Irvine-Gass syndrome after cataract surgery

Session Details

Session Title: Presented Poster Session: Training & Quality of Vision

Venue: Poster Village: Pod 3

First Author: : E.Stangogianni GREECE

Co Author(s): :    C. Stangogianni                       

Abstract Details

Purpose:

To determine whether nepafenac ophthalmic suspension 0.3% in co-administration with dexamethasone 0.1%, effectively reduces the incidence of Irvine-Gass syndrome, after uneventful cataract surgery.

Setting:

Laserlens One Day Clinic. Ioannina-Greece

Methods:

Prospective, comparative, interventional and randomized study. We included 200 eyes of 100 patients that required phacoemulsification and uncomplicated cataract surgery. Patients were randomly divided into two groups: first group (right eye) included nepafenac 0.3% + dexamethasone 0.1% ophthalmic suspension. Second group (left eye) included dexamethasone 0.1% alone. All patients received a standard regimen of moxifloxacin 0.5%. On thirtieth and ninetieth day after surgery optical coherence tomography was carried out to all patient as well in order to dismiss the presence of cystoid macular edema (CME); fluorescein retinal angiography study was performed only to confirm the CME.

Results:

Mean age was 60.97± 4.91 years. In both groups, presence of flare in the aqueous humor was found in 100% the first 24 hours. The intraocular pressure in both groups was 13.04 mmHg ± 2.23 at the first 24 hours. In group 1 the 53% of the patients referred sensation of foreign body the first and seventh day post surgery. In group 1, the patients did not develop macular edema unlike group 2 a significantly lower percentage of patients demonstrated Irvine-Gass syndrome within ninetieth day after surgery corroborated with the optical coherence tomography and fluorescein retinal angiography.

Conclusions:

We consider that the nepafenac 0,3% in co-administration with dexamethasone 0.1% is useful for the prevention of Irvine-Gass syndrome and for the control of the postoperative inflammation. This enlarges the efficacy of the anti-inflammatory therapy due to the synergic action with the different action mechanisms of these medicines, for which the joint treatment with both types of medicines turns out to appropriate. Numerous prior reports have evaluated the efficacy of this therapeutic strategy and have found an important reduction in the incidence of PCME in combined therapy with steroids in comparison with the use of only steroids.

Financial Disclosure:

None